Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review
- 16 Downloads
We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL.
We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: “positron emission tomography—PET”, “PET/CT”, “FDG”, “18F-fluorodeoxyglucose”, and “radioimmunotherapy”, ‘90Y-ibritumomab tiuxetan” and “non-Hodgkin lymphoma” and “follicular lymphoma”. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT.
The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging.
Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.
KeywordsPositron emission tomography 18F-FDG Radioimmunotherapy 90Y-ibritumomab tiuxetan
SM and SC: literature search and review, manuscript writing. LG and LR manuscript writing and editing.
This study was not funded by grants.
Compliance with ethical standards
Conflict of interest
SM received speaker honoraria from General Electric and Eli-Lilly. The other authors declare no conflict of interest.
Statement of human rights
As a review this statement is not mandatory.
- 6.Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463CrossRefGoogle Scholar
- 9.Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51CrossRefGoogle Scholar
- 10.Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner K (1999) Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. J Clin Cancer Res 5(10 Suppl):3287s–3291sGoogle Scholar
- 11.Hohloch K, Lankeit HK, Zinzani PL, Scholz CW, Lorsbach M, Windemuth-Kieselbach C et al (2014) Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur J Nucl Med Mol Imaging 41(8):1585–1592CrossRefGoogle Scholar
- 12.White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL et al (1996) Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 87(9):3640–3649Google Scholar
- 20.Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P (2005) The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 46(11):1812–1818Google Scholar
- 21.Kaneko K, Choi I, Nakagawa M, Shinozaki K, Uike N (2014) Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy? Eur Radiol 24(12):3191–3198CrossRefGoogle Scholar
- 24.Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K (2014) Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. Sci World J 2014:368947Google Scholar
- 28.Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A et al (2017) Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 102(2):356–363CrossRefGoogle Scholar
- 29.Grgic A, Nestle U, Scheidhauer K, Puskas C, Ballek E, Hohloch K (2011) Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin’s lymphoma. Nuklearmedizin 50(1):39–47CrossRefGoogle Scholar
- 31.Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P et al (2010) FDG PET and 90Y-ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging 54(4):436–441Google Scholar
- 35.Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T, Sawada A et al (2019) Early evaluation of tumor response to (90)Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT? Eur Radiol. https://doi.org/10.1007/s00330-019-06134-7 Google Scholar
- 45.Rajguru S, Kristinsdottir T, Eickhoff J, Peterson C, Meyer CM, Traynor AM et al (2014) Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol 12(8):509–515Google Scholar
- 48.Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R et al (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol 173(2):274–282CrossRefGoogle Scholar